• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

6 months ago
R&D
Cell/Gene Tx

With years­long re­or­ga­ni­za­tion be­hind it, No­var­tis in­creas­es its sales guid­ance

6 months ago
Pharma

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

6 months ago
FDA+

As­traZeneca culls Phase 2 opi­oid use dis­or­der drug

6 months ago
R&D

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

6 months ago
Pharma
FDA+

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

6 months ago
Manufacturing

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

6 months ago
Pharma
Marketing

Sam­sung Bio's new $668M client; Sanofi ex­pands a fac­to­ry in France

6 months ago
Manufacturing

Cidara's $100M PIPE; Pyx­is On­col­o­gy's stock falls on Phase 1 da­ta

6 months ago
News Briefing

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

6 months ago
Pharma

Cal­tech spin­out de­buts with AI-dri­ven 'mir­ror pep­tide' plat­form

6 months ago
R&D

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

6 months ago
Deals
R&D

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

6 months ago
People
Pharma

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

6 months ago
Deals

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

6 months ago
R&D
Pharma

Ven­rock adds $500M to health­care in­vest­ing strat­e­gy af­ter out­lin­ing 10th fund in Jan­u­ary

6 months ago
Financing
Startups

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

6 months ago
Pharma
FDA+

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

6 months ago
AI
FDA+

No­vo and Viking present new MASH da­ta, but an­a­lysts re­main con­fi­dent in Madri­gal's Rezd­if­fra

6 months ago
R&D

23andMe inks new re­search part­ner­ship as it winds down in­ter­nal drug de­vel­op­ment ef­forts

6 months ago
Deals
Health Tech

Up­dat­ed: Sage re­ports Phase 2 fail­ure in Hunt­ing­ton's dis­ease, ends drug's de­vel­op­ment

6 months ago
R&D

Pfiz­er taps on­col­o­gy head Boshoff as Dol­sten's chief sci­en­tif­ic of­fi­cer suc­ces­sor

6 months ago
People
Pharma

Car­olyn Bertozzi’s lat­est biotech de­buts with $30M seed round and a sug­ary spin on im­munother­a­py

6 months ago
Financing
Startups

Ex­clu­sive: For­mer Pfiz­er com­mer­cial chief An­gela Hwang to join Flag­ship

6 months ago
People
Startups
First page Previous page 73747576777879 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times